Press Releases

All Releases
View Summary Five Prime Therapeutics to Host Research & Development Day on December 8, 2016
Wednesday, November 30, 2016
PDF 15.8 KB Add to Briefcase
View Summary Five Prime to Present Preclinical Data at 2016 SITC Annual Meeting Demonstrating Potent Anti-Tumor Activity with Novel Tetravalent Anti-GITR Antibody
Friday, November 11, 2016
PDF 15.5 KB Add to Briefcase
View Summary Five Prime Announces Third Quarter 2016 Results and Provides Business Update
Thursday, November 3, 2016
PDF 26.7 KB Add to Briefcase
View Summary Five Prime to Present Preclinical Data at 2016 SITC Annual Meeting For Novel Tetravalent Anti-GITR Antibody
Thursday, November 3, 2016
PDF 11.7 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the 25th Annual Credit Suisse Healthcare Conference
Wednesday, October 26, 2016
PDF 9.1 KB Add to Briefcase
View Summary Five Prime Therapeutics to Announce Third Quarter 2016 Financial Results and Host Conference Call on November 3
Thursday, October 20, 2016
PDF 9.1 KB Add to Briefcase
View Summary Five Prime Therapeutics Advances into Phase 1b Portion of Trial Evaluating the Immunotherapy Combination of Cabiralizumab (FPA008) and OPDIVO (nivolumab) in Multiple Tumor Types
Tuesday, October 4, 2016
PDF 12.6 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the LEERINK Partners Rare Disease & Immuno-Oncology Roundtable
Thursday, September 22, 2016
PDF 9.7 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Key Executive Promotions
Tuesday, September 20, 2016
PDF 15.5 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the Morgan Stanley Global Healthcare Conference
Tuesday, September 6, 2016
PDF 9.8 KB Add to Briefcase
View Summary Five Prime Announces Second Quarter 2016 Results and Provides Business Update
Thursday, August 4, 2016
PDF 28.0 KB Add to Briefcase
View Summary Five Prime Therapeutics to Announce Second Quarter 2016 Financial Results and Host Conference Call on August 4
Monday, July 18, 2016
PDF 9.1 KB Add to Briefcase
View Summary GSK Exclusively Licenses Intellectual Property for Respiratory Disease Target Identified Using Five Prime's Proprietary Protein Discovery Platform
Thursday, July 14, 2016
PDF 12.8 KB Add to Briefcase
View Summary Five Prime Therapeutics Receives FDA Orphan Drug Designation for FPA144 for the Treatment of Gastric Cancer
Tuesday, July 5, 2016
PDF 13.0 KB Add to Briefcase
View Summary Five Prime Therapeutics to Use Proprietary Protein Discovery Platform to Identify New Factors that Generate Hematopoietic Stem Cells in Collaboration with the University of Minnesota Medical School
Monday, June 27, 2016
PDF 13.8 KB Add to Briefcase
View Summary Five Prime Therapeutics Presents Updated Data from Phase 1 trial of Single-Agent FPA144 at 2016 ASCO Annual Meeting
Monday, June 6, 2016
PDF 19.8 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting
Saturday, June 4, 2016
PDF 17.0 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the Jefferies 2016 Healthcare Conference
Thursday, June 2, 2016
PDF 9.2 KB Add to Briefcase
View Summary Five Prime Therapeutics Appoints Dr. Robert Sikorski as Chief Medical Officer
Wednesday, June 1, 2016
PDF 11.9 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Updated Clinical Data on FPA144 and FP-1039 to be Presented during 2016 ASCO Annual Meeting
Wednesday, May 18, 2016
PDF 15.5 KB Add to Briefcase
Showing 41-60 of 191 Page: 1 2 3 4 5 6 7 ... 10  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

FPRX (Common Stock)

Exchange
NASDAQ
Price
25.56
Change (%)
-0.20
Volume
409,193

Data as of 4:00 PM ET on Friday, November 17, 2017
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.